• According to a report by the Food & Drug Administration, some medicines may contain ingredients that cause photosensitivity -- photosensitivity is what makes a person sensitive to sunlight and cause rashes or other unwanted effects like sunburn-like symptoms -- and a range of products, including those applied to the skin or any medicines taken by the mouth or injected, can cause these side effects.

  • The drug life-cycle of the 4.3 billion prescriptions Americans fill out every year is not over until the medicine has been consumed in its entirety or discarded of properly; accidental exposure or intentional misuses are direct results of improper medicine disposal, but, thankfully, Deputy Director for Regulatory Programs in the Center for Drug Evaluation and Research at the FDA Dr. Douglas Throckmorton knows how best to dispose and take care of them.

  • GlaxoSmithKline has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given a positive opinion that recommends marketing authorization; Mepolizumab will be commercialized under the name Nucala, and the group will become an add-on treatment for severe refractory eosinophilic asthma found in adult patients.

  • The U.S. Food and Drug Administration (FDA) recently approved VRAYLAR (cariprazine) capsules, an atypical antipsychotic intended for acute treatment of manic or mixed episodes stemming from bipolar I disorder and general treatment of schizophrenia in adults, Allergan Plc and Gedeon Richter Plc announced.

  • Bayer HealthCare has announced that  it will be showcasing the data its procured from its oncology franchise portfolio at the 2015 European Cancer Congress (ECC2015) on Sept. 25-29 in Vienna.

  • Ferring Pharmaceuticals recently announced it will begin Phase 2b/3 trials of Selepressin, a treatment intended to treat septic shock, at 50 to 60 sites between Europe and the United States, enrolling 1,800 patients to take place in the trials.